A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
Syndesi Therapeutics, a Belgium-based developer of therapies to treat cognitive impairment, was acquired by pharmaceutical firm AbbVie yesterday for $130m upfront, with the potential for up to $870m in milestones. The agreement provided an exit to Vives Louvain Technology Fund, the university venture fund of Université Catholique de Louvain, and V-Bio Ventures, the venture capital firm linked to research institute VIB. Syndesi last raised $21m in a series A round backed by the two aforementioned investors in February…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
